Inactive Instrument

Rubius Therapeutics

RUBY

US78116T1034

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Rubius Therapeutics

North American Morning Briefing : Stock Futures -2-	23-08-22	DJ
North American Morning Briefing : China Angst -2-	23-08-15	DJ
North American Morning Briefing : Sentiment Hit by -2-	23-08-08	DJ
North American Morning Briefing : Latest China -2-	23-08-01	DJ
North American Morning Briefing : Alphabet, -2-	23-07-25	DJ
North American Morning Briefing : Fresh Batch of -2-	23-07-18	DJ
North American Morning Briefing : Beijing Boost Supports Mood; CPI Still The Main Event	23-07-11	DJ
North American Morning Briefing : Stock Futures -2-	23-06-27	DJ
North American Morning Briefing : Stock Futures -2-	23-06-20	DJ
North American Morning Briefing : Investors Brace -2-	23-06-13	DJ
North American Morning Briefing : Stocks Poised -2-	23-05-30	DJ
North American Morning Briefing : Stock Futures -2-	23-05-23	DJ
North American Morning Briefing : Retail Sales, -2-	23-05-16	DJ
Rubius Therapeutics, Inc. Announces Resignation of Pablo J. Cagnoni, M.D. as Member of Board of Directors	23-04-06	CI
Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from S&P TMI Index	23-03-09	CI
Upcoming Powell Testimony to Congress Underpins US Equity Futures	23-03-06	MT
Top Premarket Decliners	23-03-06	MT
Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from NASDAQ Composite Index	23-03-06	CI
Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from Russell 3000E Index	23-03-06	CI
Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from Russell Microcap Value Index	23-03-06	CI
Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from Russell 3000E Value Index	23-03-06	CI
Rubius Therapeutics, Inc.(OTCPK:RUBY) dropped from Russell Microcap Index	23-03-06	CI
Rubius Therapeutics, Inc. Announces Board Changes	23-03-03	CI
Rubius Therapeutics, Inc. Announces CEO Changes	23-03-03	CI
Rubius Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI

Rubius Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing a platform and pipeline that is focused on creating cellular medicines called Red Cell Therapeutics. The Company's Red Cell Therapeutics are engineered to express biotherapeutic proteins within or on their cell surface to create selective and allogeneic cellular medicines for treating a range of diseases. Red Cell Therapeutics can also be used to kill tumors in cancer, regulate the immune system for the treatment of autoimmune diseases and treat a number of other types of illnesses. The Company's subsidiary is Rubius Therapeutics Securities Corporation.

Sector

More about the company

Rubius Therapeutics

Equities

RUBY

US78116T1034

Latest news about Rubius Therapeutics

Chart Rubius Therapeutics

Company Profile